【Asset for Licensing】Orally bioavailable selective KRAS G12D small-molecule inhibitor

Asset: Orally bioavailable selective KRAS G12D small-molecule inhibitor
Development Stage: Clinical stage
Indication: Colorectal Cancer (CRC), Lung Cancer and Pancreatic Cancer
Key Asset Highlights:
（1）Exhibits high selectivity and potent inhibitory activity against KRAS G12D, one of the most prevalent and challenging oncogenic drivers across multiple solid tumors, with minimal off-target interference on wild-type KRAS and other mutants.
（2）Effectively blocks downstream RAS/RAF/MEK/ERK signaling cascade, inducing robust tumor growth suppression and regression in preclinical and clinical models of KRAS G12D-mutant CRC, lung and pancreatic cancers.
（3）Delivers encouraging clinical anti-tumor efficacy in heavily treated refractory solid tumors, filling the unmet clinical need for targeted therapy in KRAS G12D-driven malignancies with limited treatment options.
（4）Demonstrates prominent synergistic anti-tumor potential in combination with mainstream targeted agents and chemotherapy, enabling diversified oral combination regimens to further improve clinical response rates.
（5）Possesses superior oral pharmacokinetic properties and a well-tolerated safety profile, supporting convenient outpatient oral administration and sustainable long-term clinical treatment.
Protected by a comprehensive and robust intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for KRAS G12D-mutant solid tumor indications.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.